Related references
Note: Only part of the references are listed.FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia
Jun Long et al.
BLOOD (2020)
Phase II study of FLAGM (fludarabine plus high-dose cytarabine plus granulocyte colony-stimulating factor plus mitoxantrone) for relapsed or refractory acute myeloid leukemia
Nahoko Hatsumi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial
Jan Moritz Middeke et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
David Grimwade et al.
BLOOD (2016)
Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation
Francine E. Garrett-Bakelman et al.
EPIGENOMICS (2016)
The alternative role of DNA methylation in splicing regulation
Galit Lev Maor et al.
TRENDS IN GENETICS (2015)
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
Xuejie Jiang et al.
ONCOTARGET (2015)
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Jianyong Li et al.
ONCOTARGET (2015)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Mark Kirschbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
De-Si Pan et al.
MEDCHEMCOMM (2014)
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2013)
Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives
Giuseppe Giannini et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
Haifa K. Al-Ali et al.
LEUKEMIA & LYMPHOMA (2012)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
Saiko Kurosawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
Outcome of patients with acute myelogenous leukemia after second salvage therapy
F Giles et al.
CANCER (2005)
Share Paper
